Volume 11, Number 6—June 2005
Diversification in Salmonella Typhimurium DT104
To the Editor: Multidrug-resistant (MDR) Salmonella Typhimurium definitive phage type (DT) 104 with chromosomally encoded resistance to ampicillin, chloramphenicol, streptomycin/spectinomycin, sulfonamides, and tetracyclines (ACSSpSuT) was first identified and characterized in the United Kingdom in the early 1990s (1). MDR DT104 has subsequently caused numerous outbreaks throughout the world (1). The organism is characterized by a distinctive Xba I-generated pulsed-field profile (PFP), designated Xtm 1 (2), carriage of the 90-kb S. Typhimurium serovar-specific plasmid (SSP), and presence of the 43-kb Salmonella genomic island 1 (SGI 1), which is composed of integrons containing, respectively, the ASu (blaCARB-2 and sul1) and SSp (aadA2) genes, with intervening plasmid-derived genes coding for chloramphenicol/florfenicol (cmlA) and tetracycline resistance (tetG) (1,3,4). The same genetic characteristics have been observed in MDR strains of the closely related DTs 12 and 104b (5) and in some strains of phage type U302 (4). All isolates of MDR DT104 ACSSpSuT contain the same gene cassettes irrespective of source or country of origin. Although MDR DT104 has declined during the last 5 years, the organism remains the most common MDR Salmonella in the United Kingdom and many other European countries (6).
Since 1998, MDR DT104 has undergone changes in both resistance spectrum and genetic structure. In the United Kingdom, outbreaks of MDR DT104 have been caused by new subclones with additional resistance to trimethoprim (Tm) (R-type ACSSpSuTTm) (7), by clones with decreased susceptibility to ciprofloxacin (CpL) (R-type ACSSpSuTCpL) (1), and by strains of R-type SSpSu. In 2002, an outbreak of MDR DT104 ACSSpSuTTm with >200 cases was recognized (7). The outbreak strain was characterized by 3 plasmids of 6.8, 3.0, and 1.5 kb. The 6.8-kb plasmid coded for resistance to sulfonamides and trimethoprim, with trimethoprim resistance being mediated by dhfr1b. The outbreak strain lacked the S. Typhimurium SSP and was negative by polymerase chain reaction (PCR) for a 437-bp internal fragment of the Salmonella plasmid virulence (spv)C gene. The absence of the SSP was reflected in the PFP, which was identical to Xtm 1 but lacked a fragment of ≈90 kb that corresponds to the presence of the SSP (4). A strain of R-type ACSSpSuT that also lacked the SSP and with a PFP indistinguishable from that of the ACSSpSuTTm strain caused a simultaneous outbreak with >40 cases (7). This strain was also characterized by 2 plasmids of 3.0 and 1.5 kb but did not possess the 6.8-kb sulfonamide-trimethoprim resistance plasmid.
Decreased susceptibility to ciprofloxacin coupled with resistance to nalidixic acid (Nx) was first reported in MDR DT104 in 1996 in the United Kingdom (1). Four mutations in gyrA, each giving rise to resistance to Nx/CpL, were subsequently identified in MDR DT104. The most common mutation was aspartate (Asp)-87 to asparagine (AAC) and involved a change from aspartate (GAC) to AAC. An identical mutation was identified in a MDR DT104 strain responsible for an outbreak in Denmark in 1998 (8). In 1999, an Asp-87 to glycine mutation was identified in a CpL MDR DT104 strain responsible for a major outbreak in northwestern England (1). Subsequently, >500 sporadic MDR DT104 infections in the United Kingdom have involved strains with CpL.
In 2004, 2 simultaneous outbreaks of DT104 were recorded in the United Kingdom in which the strains were of R-type SSpSu, 1 involving >100 cases and 1 involving >50 cases. Isolates were characterized by pulsed-field gel electrophoresis coupled with plasmid profile analysis. Resistance genes were identified by using PCR with primers specific for blaTEM (A), blaCARB-2, cmlA, catI (C), catIII (C), aadA2, sul1, and tetG (4). Testing for SGI1 was conducted by using primers U7-L12 and LJ-R1 for the left junction and primers 104-RJ and 104-D for the right junction (9). All isolates exhibited the Xtm 1 PFP, but strains from the 2 outbreaks could be differentiated by the presence or absence of an additional plasmid of ≈3 kb. By using PCR, all isolates possessed aadA2 and sul1 but were negative for blaTEM,blaCARB-2, cmlA, catI, catIII, and tetG. Similarly, all strains were positive for the left junction of SGI1. These results indicate that the SGI1 was in the same chromosomal location as for DT104 ACSSpSuT but was lacking the right junction.
These findings demonstrate that evolutionary changes have occurred involving both loss and acquisition of drug resistance genes, the development of chromosomal mutations conferring resistance to Nx/CpL, and in certain subclones, the loss of the SSP. None of these changes has altered the virulence of the organism, with bloodstream invasion in only 1.6% of 408 cases in the United Kingdom. These findings contrast with those in the United States, where MDR nontyphoidal Salmonella have been associated with excessive numbers of bloodstream infections (10).
All facets of the organism should be explored for epidemiologic investigations. These should include phage type, antibiogram, plasmid profile, and PFP, coupled with the identification of resistance genes and integrons, and, when appropriate, the characterization of mutations conferring resistance to quinolone antimicrobial agents.
These studies were in part supported by a grant from the Department for Environment, Foods and Rural Affairs, reference V02136.
- Threlfall EJ. Epidemic Salmonella typhimurium DT104 - a truly international epidemic clone. J Antimicrob Chemother. 2000;46:7–10.
- Lawson AJ, Desai M, O'Brien SJ, Davies RH, Ward LR, Threlfall EJ. Molecular characterisation of an outbreak strain of multiresistant Salmonella enterica serovar Typhimurium DT104 in the UK. Clin Microbiol Infect. 2004;10:143–7.
- Briggs CE, Fratamico PM. Molecular characterization of an antibiotic resistance gene cluster of Salmonella typhimurium DT104. Antimicrob Agents Chemother. 1999;43:846–9.
- Walker RA, Lindsay E, Woodward MJ, Ward LR, Threlfall EJ. Variation in clonality and antibiotic resistance genes among multiresistant Salmonella enterica serotype typhimurium phage type U302 (MR U302) from humans, animals and foods. Microb Drug Resist. 2001;7:13–21.
- Lawson AJ, Dessama MU, Ward LR, Threlfall EJ. Multiple resistant Salmonella enterica serovar Typhimurium DT12 and 120: a case of MR DT104 in disguise? Emerg Infect Dis. 2002;8:434–6.
- Threlfall EJ, Fisher IST, Berghold C, Gerner-Smidt P, Tschape H, Cormican M, Antimicrobial drug resistance in Salmonella enterica in Europe in 2000: results of international multi-centre surveillance. Eurosurveillance. 2003;8:41–5.
- Threlfall EJ, Hampton MD, Chart H, Hopkins K, Ward LR, Tebbutt G. Emergence of new subclones of multiresistant S. typhimurium DT104 possibly associated with poultry. Vet Rec. 2004;154:89–90.
- Mølbak K, Baggesen DL, Aarestrup FM, Ebbesen JM. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype Typhimurium DT104. N Engl J Med. 1999;341:1420–5.
- Boyd D, Cloeckaert A, Chaslus-Dancla E, Mulvey MR. Characterisation of variant Salmonella genomic island 1 multidrug resistance regions from serovars Typhimurium DT104 and Agona. Antimicrob Agents Chemother. 2002;46:1714–22.
- Varma JK, Mølbak K, Barrett TJ, Jones TK. Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations. J Infect Dis. 2005;191:554–61.
Suggested citation for this article: Threlfall J, Hopkins KL, Ward LR. Diversification in Salmonella Typhimurium DT104 [letter]. Emerg Infect Dis [serial on the Internet]. 2005 Jun [date cited]. http://dx.doi.org/10.3201/eid1106.050100
Please use the form below to submit correspondence to the authors or contact them at the following address:
John Threlfall, Health Protection Agency Centre for Infections, Laboratory of Enteric Pathogens, Specialist and Reference Microbiology Division, 61 Colindale Ave, London NW9 5HT, United Kingdom; fax: 44-208-905-9929
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: April 24, 2012
- Page last updated: April 24, 2012
- Page last reviewed: April 24, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)